Evidence map›Paper›PMID 31147732›Full record

ArticleRheumatology international2019

Pharmacist-managed titration of urate-lowering therapy to streamline gout management.

Irvin J Huang, Jean W Liew, Meredith B Morcos, Silu Zuo, Carol Crawford, Alison M Bays

Abstract read
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. The art and science of drug titration.Therapeutic advances in drug safety · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Irvin J HuangDepartment of Medicine, University of Washington, Boise, ID, USA.ORCID http://orcid.org/0000-0002-8094-3919
Jean W LiewDivision of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, USA. jwliew@uw.edu.ORCID http://orcid.org/0000-0002-8104-2450
Meredith B MorcosRheumatology, Virginia Mason Medical Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-9462-2078
Silu ZuoPharmacy, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-1445-6848
Carol CrawfordPharmacy, Harborview Medical Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-1324-5173
Alison M BaysDivision of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-7193-6303
University of Washington · USHarborview Medical Center · USVirginia Mason Medical Center · US

Funding

National Institutes of Health T32AR007108
6 · The paper itself

Abstract

The treat-to-target approach for serum uric acid is the recommended model in gout management according to the 2012 American College of Rheumatology (ACR) guidelines. Adherence to urate-lowering therapy (ULT) can be difficult for patients due to barriers, which include medication burden, financial hardship, and lack of medical literacy. Our aim was to create a pharmacist-managed referral for the titration of ULT to target serum uric acid (sUA) levels in a complex patient population. We utilized a clinical database to query patients seen at a rheumatology clinic over a 12-month period with an ICD-10 diagnosis for gout. The referral criteria were indications for ULT per the 2012 ACR guidelines. Rheumatology providers, consisting of attendings, fellows, and a physician assistant, were asked to refer the identified patients to the pharmacist-managed titration program. The intervention group consisted of 19 referred patients and the control group consisted of 28 non-referred patients. The baseline sUA (median (IQR)) at the time of referral was 8.8 (2) mg/dL for the intervention group and 7.6 (2.8) mg/dL for the control group (p = 0.2). At the end of the study period, the sUA was 6.1 (1.4) mg/dL for the intervention group and 6.8 (3.2) mg/dL for the control group (p = 0.08). At the end of the study period, 6 of 19 (32%) intervention group and 7 of 28 (25%) control group were at goal (p = 0.3). A newly instituted pharmacist-managed titration program was able to achieve lower average sUA levels in referred patients compared to demographically similar individuals who received standard gout management.

Indexed as

PharmacistsProfessional RoleAdultAgedBiomarkersDatabases, FactualDown-RegulationFemaleGoutGout SuppressantsHumansHyperuricemiaMaleMiddle AgedProgram EvaluationReferral and ConsultationBiomarkersGout SuppressantsUric AcidCrystal arthropathiesGoutHyperuricemiaPatient compliance

Identifiers

PMID31147732
OpenAlexW2947314058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.